DOJOLVI
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 13 Feb 2026)
What this means for you
Registered since 10 Nov 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88707194
- Registration number
- 6196836
- Mark type
- Design + words
- Filed
- 26 Nov 2019
- Published for opposition
- 07 Apr 2020
- Registered
- 10 Nov 2020
- Attorney of record
- Brian Focarino
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in treating genetic disorders, autosomal disorders, lysosomal storage disorders, metabolic disorders, energy deficiency disorders, and enzyme disorders; pharmaceuticals for use in treating long-chain fatty acid oxidation disorders (LC-FAOD)
Owner
- Ultragenyx Pharmaceutical Inc., Novato, CA, US
- Ultragenyx Pharmaceutical Inc., Novato, CA, US
- Ultragenyx Pharmaceutical Inc., Novato, CA, US
Prosecution history
- 13 Feb 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 13 Feb 2026 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 13 Feb 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 11 Nov 2025 — TEAS SECTION 8 & 15 RECEIVED
- 10 Nov 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 02 Aug 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 02 Aug 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 02 Aug 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 02 Aug 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 02 Aug 2024 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 10 Nov 2020 — REGISTERED-PRINCIPAL REGISTER
- 03 Oct 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 02 Oct 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Sept 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Sept 2020 — STATEMENT OF USE PROCESSING COMPLETE